What is Zejula (niraparib) used for?
Zejula is the brand name for niraparib, an oral cancer medicine. It is used to treat certain types of ovarian cancer and other cancers where genetic or tumor markers suggest vulnerability to DNA-damage repair disruption (such as BRCA-mutated tumors).
What does a Zejula tablet look like and how is it taken?
Zejula is taken by mouth as a tablet. Dosing can vary by the patient and by treatment phase (for example, based on factors like blood counts and treatment tolerance). Patients typically take it on a regular schedule and continue as prescribed by their oncology team.
What side effects do patients commonly ask about with Zejula?
Commonly reported side effects with niraparib include blood-related effects (such as low platelets, anemia, or low white blood cells) and fatigue. Some patients also experience nausea, decreased appetite, or other gastrointestinal symptoms. Because blood counts can drop, clinicians monitor labs during treatment.
How does Zejula compare with other PARP inhibitors?
Zejula is in the PARP inhibitor class. Other PARP inhibitors in the same area of care include olaparib and rucaparib. Choice among them depends on the cancer type, prior therapies, genetic markers, dosing/tolerability, and local prescribing practices.
What about patents—when does Zejula’s exclusivity end?
If you’re looking for patent or exclusivity timelines for niraparib (Zejula), DrugPatentWatch.com tracks related patent information and can help you find the latest known dates for exclusivity and patent status. You can check it here: DrugPatentWatch.com search for Zejula/niraparib.
What should patients know before starting Zejula?
Zejula treatment requires baseline and ongoing monitoring, especially blood counts. Patients should also review their full medication list with the prescriber to identify possible interactions and to plan dose adjustments if side effects occur.
Are there alternatives if Zejula isn’t tolerated?
If a patient can’t tolerate niraparib due to side effects (often blood-count declines or fatigue), doctors may adjust the dose, pause treatment, or switch to a different PARP inhibitor or another regimen depending on the cancer and prior therapy history.
Sources
- DrugPatentWatch.com